Myeloid cell distribution and activity in multiple sclerosis

Histology and Histopathology

Volumn 31, Issue 4, 2016, Pages 357-370

  Moliné Velázquez, Verónica ^a,b   Vila del Sol, Virginia ^a   De Castro, Fernando ^a   Clemente, Diego ^a  

^a HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Demyelinaion; Dendritic cells; EAE; Functionality; Macrophages; MDSCs; Myelin; Neutrophils; Remyelination

Indexed keywords

ANIMAL; BONE MARROW CELL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; MULTIPLE SCLEROSIS; PATHOLOGY;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; MYELOID CELLS;

EID: 84958970728     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: 10.14670/HH-11-699     Document Type: Review

References (126)

1. Ajami B., Bennett J.L., Krieger C., McNagny K.M. and Rossi F.M. (2011). Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat. Neurosci. 149, 1142-1149.
2. Allen S.J., Baker D., O'Neill J.K., Davison A.N. and Turk J.L. (1993). Isolation and characterization of cells infiltrating the spinal cord during the course of chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse. Cell Immunol. 1462, 335-350.
3. Almolda B., Gonzalez B. and Castellano B. (2011). Antigen presentation in EAE: role of microglia, macrophages and dendritic cells. Front Biosci. (Landmark. Ed) 16, 1157-1171.
4. Ambarus C.A., Krausz S., van E.M., Hamann J., Radstake T.R., Reedquist K.A., Tak P.P. and Baeten D.L. (2012). Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J. Immunol. Methods 3751-2, 196-206.
5. Amulic B., Cazalet C., Hayes G.L., Metzler K.D. and Zychlinsky A. (2012). Neutrophil function: from mechanisms to disease. Annu. Rev. Immunol. 30, 459-489.
6. Angulo I., de las Heras F.G., Garcia-Bustos J.F., Gargallo D., Munoz-Fernandez M.A. and Fresno M. (2000). Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood 951, 212-220.
7. Aoki Y., Miyatake T., Shimizu N. and Yoshida M. (1984). Medullasin activity in granulocytes of patients with multiple sclerosis. Ann. Neurol. 153, 245-249.
8. Aube B., Levesque S.A., Pare A., Chamma E., Kebir H., Gorina R., Lecuyer M.A., Alvarez J.I., De K.Y., Engelhardt B., Prat A., Cote D. and Lacroix S. (2014). Neutrophils mediate blood-spinal cord barrier disruption in demyelinating neuroinflammatory diseases. J. Immunol. 1935, 2438-2454.
9. Baker D., Gerritsen W., Rundle J. and Amor S. (2011). Critical appraisal of animal models of multiple sclerosis. Mult. Scler. 176, 647-657.
10. Barnett M.H., Henderson A.P. and Prineas J.W. (2006). The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion. Mult. Scler. 122, 121-132.
11. Batoulis H., Addicks K. and Kuerten S. (2010). Emerging concepts in autoimmune encephalomyelitis beyond the CD4/T(H)1 paradigm. Ann. Anat. 1924, 179-193.
12. Baxter A.G. (2007). The origin and application of experimental autoimmune encephalomyelitis. Nat. Rev. Immunol. 711, 904-912.
13. Benito C., Romero J.P., Tolon R.M., Clemente D., Docagne F., Hillard C.J., Guaza C. and Romero J. (2007). Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J. Neurosci. 279, 2396-2402.
14. Berard J.L., Wolak K., Fournier S. and David S. (2010). Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice. Glia 584, 434-445.
15. Bramow S., Frischer J.M., Lassmann H., Koch-Henriksen N., Lucchinetti C.F., Sorensen P.S. and Laursen H. (2010). Demyelination versus remyelination in progressive multiple sclerosis. Brain 13310, 2983-2998.
16. Breij E.C., Brink B.P., Veerhuis R., van den Berg C., Vloet R., Yan R., Dijkstra C.D., van der Valk P. and Bo L. (2008). Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann. Neurol. 631, 16-25.
17. Bronte V. and Zanovello P. (2005). Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 58, 641-654.
18. Bulloch K., Miller M.M., Gal-Toth J., Milner T.A., Gottfried-Blackmore A., Waters E.M., Kaunzner U.W., Liu K., Lindquist R., Nussenzweig M.C., Steinman R.M. and McEwen B.S. (2008). CD11c/EYFP transgene illuminates a discrete network of dendritic cells within the embryonic, neonatal, adult, and injured mouse brain. J. Comp Neurol. 5085, 687-710.
19. Cannella B. and Raine C.S. (1995). The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 374, 424-435.
20. Chang A., Tourtellotte W.W., Rudick R. and Trapp B.D. (2002). Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med. 3463, 165-173.
21. Chang A., Smith M.C., Yin X., Fox R.J., Staugaitis S.M. and Trapp B.D. (2008). Neurogenesis in the chronic lesions of multiple sclerosis. Brain 131, 2366-2375.
22. Clarkson B.D., Walker A., Harris M.G., Rayasam A., Sandor M. and Fabry Z. (2015). CCR2-dependent dendritic cell accumulation in the central nervous system during early effector experimental autoimmune encephalomyelitis is essential for effector T cell restimulation in situ and disease progression. J. Immunol. 1942, 531-541.
23. Clemente D., Ortega M.C., Arenzana F.J. and de Castro F. (2011). FGF-2 and Anosmin-1 are selectively expressed in different types of multiple sclerosis lesions. J. Neurosci. 3142, 14899-14909.
24. Colton C.A. (2013). Immune heterogeneity in neuroinflammation: dendritic cells in the brain. J. Neuroimmune. Pharmacol. 81, 145-162.
25. Compston A. and Coles A. (2008). Multiple sclerosis. Lancet 3729648, 1502-1517.
26. Constantinescu C.S., Farooqi N., O'Brien K. and Gran B. (2011). Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br. J. Pharmacol. 1644, 1079-1106.
27. Cripps J.G. and Gorham J.D. (2011). MDSC in autoimmunity. Int. Immunopharmacol. 117, 789-793.
28. Croxford A.L., Kurschus F.C. and Waisman A. (2011). Mouse models for multiple sclerosis: historical facts and future implications. Biochim. Biophys. Acta 18122, 177-183.
29. De Groot C.J., Ruuls S.R., Theeuwes J.W., Dijkstra C.D., van der Valk P. and Addicks K. (1997). Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 561, 10-20.
30. Delano M.J., Scumpia P.O., Weinstein J.S., Coco D., Nagaraj S., Kelly-Scumpia K.M., O'Malley K.A., Wynn J.L., Antonenko S., Al-Quran S.Z., Swan R., Chung C.S., Atkinson M.A., Ramphal R., Gabrilovich D.I., Reeves W.H., Ayala A., Phillips J., Laface D., Heyworth P.G., Clare-Salzler M. and Moldawer L.L. (2007). MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 2046, 1463-1474.
31. Denney L., Kok W.L., Cole S.L., Sanderson S., McMichael A.J. and Ho L.P. (2012). Activation of invariant NKT cells in early phase of experimental autoimmune encephalomyelitis results in differentiation of Ly6Chi inflammatory monocyte to M2 macrophages and improved outcome. J. Immunol. 1892, 551-557.
32. Duffy S.S., Lees J.G. and Moalem-Taylor G. (2014). The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis. Mult. Scler. Int. 2014, 285245.
33. Durafourt B.A., Moore C.S., Zammit D.A., Johnson T.A., Zaguia F., Guiot M.C., Bar-Or A. and Antel J.P. (2012). Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia 605, 717-727.
34. Fabriek B.O., Van Haastert E.S., Galea I., Polfliet M.M., Dopp E.D., Van Den Heuvel M.M., van den Berg T.K., De Groot C.J., van der Valk P. and Dijkstra C.D. (2005). CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. Glia 514, 297-305.
35. Frischer J.M., Bramow S., Dal-Bianco A., Lucchinetti C.F., Rauschka H., Schmidbauer M., Laursen H., Sorensen P.S. and Lassmann H. (2009). The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132, 1175-1189.
36. Frohman E.M., Racke M.K. and Raine C.S. (2006). Multiple sclerosis--the plaque and its pathogenesis. N. Engl. J. Med. 3549, 942-955.
37. Gabrilovich D.I. and Nagaraj S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 93, 162-174.
38. Gabrilovich D.I., Ostrand-Rosenberg S. and Bronte V. (2012). Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 124, 253-268.
39. Gerritse K., Laman J.D., Noelle R.J., Aruffo A., Ledbetter J.A., Boersma W.J. and Claassen E. (1996). CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. USA 936, 2499-2504.
40. Goni O., Alcaide P. and Fresno M. (2002). Immunosuppression during acute Trypanosoma cruzi infection: involvement of Ly6G (Gr1(+))CD11b(+)immature myeloid suppressor cells. Int. Immunol. 1410, 1125-1134.
41. Goverman J. (2009). Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 96, 393-407.
42. Greter M., Heppner F.L., Lemos M.P., Odermatt B.M., Goebels N., Laufer T., Noelle R.J. and Becher B. (2005). Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 113, 328-334.
43. Guarnieri B., Lolli F. and Amaducci L. (1985). Polymorphonuclear neutral protease activity in multiple sclerosis and other diseases. Ann. Neurol. 185, 620-622.
44. Guo L.H. and Schluesener H.J. (2005). Lesional accumulation of P2X(4) receptor(+) macrophages in rat CNS during experimental autoimmune encephalomyelitis. Neuroscience 1341, 199-205.
45. Henderson A.P., Barnett M.H., Parratt J.D. and Prineas J.W. (2009). Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann. Neurol. 666, 739-753.
46. Heppner F.L., Greter M., Marino D., Falsig J., Raivich G., Hovelmeyer N., Waisman A., Rulicke T., Prinz M., Priller J., Becher B. and Aguzzi A. (2005). Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat. Med. 112, 146-152.
47. Herges K., de Jong B.A., Kolkowitz I., Dunn C., Mandelbaum G., Ko R.M., Maini A., Han M.H., Killestein J., Polman C., Goodyear A.L., Dunn J., Steinman L. and Axtell R.C. (2012). Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult. Scler. 184, 398-408.
48. Hesske L., Vincenzetti C., Heikenwalder M., Prinz M., Reith W., Fontana A. and Suter T. (2010). Induction of inhibitory central nervous system-derived and stimulatory blood-derived dendritic cells suggests a dual role for granulocyte-macrophage colony-stimulating factor in central nervous system inflammation. Brain 133, 1637-1654.
49. Hulshof S., Montagne L., De Groot C.J. and van der Valk P. (2002). Cellular localization and expression patterns of interleukin-10, interleukin-4, and their receptors in multiple sclerosis lesions. Glia 381, 24-35.
50. Inglese M. (2006). Multiple sclerosis: new insights and trends. Am. J. Neuroradiol. 275, 954-957.
51. Ioannou M., Alissafi T., Lazaridis I., Deraos G., Matsoukas J., Gravanis A., Mastorodemos V., Plaitakis A., Sharpe A., Boumpas D. and Verginis P. (2012). Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. J. Immunol. 1883, 1136-1146.
52. Irla M., Kupfer N., Suter T., Lissilaa R., Benkhoucha M., Skupsky J., Lalive P.H., Fontana A., Reith W. and Hugues S. (2010). MHC class II-restricted antigen presentation by plasmacytoid dendritic cells inhibits T cell-mediated autoimmunity. J. Exp. Med. 2079, 1891-1905.
53. Jiang Z., Jiang J.X. and Zhang G.X. (2014). Macrophages: a doubleedged sword in experimental autoimmune encephalomyelitis. Immunol. Lett. 1601, 17-22.
54. Jurynczyk M., Craner M. and Palace J. (2015). Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. J. Neurol. Neurosurg. Psychiatry 861, 20-25.
55. Kalyan S. and Kabelitz D. (2014). When neutrophils meet T cells: beginnings of a tumultuous relationship with underappreciated potential. Eur. J. Immunol. 443, 627-633.
56. King I.L., Dickendesher T.L. and Segal B.M. (2009). Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 11314, 3190-3197.
57. Koning N., Bo L., Hoek R.M. and Huitinga I. (2007). Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions. Ann. Neurol. 625, 504-514.
58. Lassmann H. (2013). Pathology and disease mechanisms in different stages of multiple sclerosis. J. Neurol. Sci. 333, 1-4.
59. Lassmann H., van H.J. and Mahad D. (2012). Progressive multiple sclerosis: pathology and pathogenesis. Nat. Rev. Neurol. 811, 647-656.
60. Lee P.Y., Wang J.X., Parisini E., Dascher C.C. and Nigrovic P.A. (2013). Ly6 family proteins in neutrophil biology. J. Leukoc. Biol. 944, 585-594.
61. Liu C., Li Y., Yu J., Feng L., Hou S., Liu Y., Guo M., Xie Y., Meng J., Zhang H., Xiao B. and Ma C. (2013). Targeting the shift from M1 to M2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil. PLoS One 82, e54841.
62. London A., Benhar I., Mattapallil M.J., Mack M., Caspi R.R. and Schwartz M. (2013). Functional macrophage heterogeneity in a mouse model of autoimmune central nervous system pathology. J. Immunol. 1907, 3570-3578.
63. Lucchinetti C.F., Mandler R.N., McGavern D., Bruck W., Gleich G., Ransohoff R.M., Trebst C., Weinshenker B., Wingerchuk D., Parisi J.E. and Lassmann H. (2002). A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125, 1450-1461.
64. Maatta J.A., Eralinna J.P., Roytta M., Salmi A.A. and Hinkkanen A.E. (1996). Physical state of the neuroantigen in adjuvant emulsions determines encephalitogenic status in the BALB/c mouse. J. Immunol. Methods 1901, 133-141.
65. Makarenkova V.P., Bansal V., Matta B.M., Perez L.A. and Ochoa J.B. (2006). CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J. Immunol. 1764, 2085-2094.
66. Martínez-Gómez J.M., Croxford J.L., Yeo K.P., Angeli V., Schwarz H. and Gasser S. (2012). Development of experimental autoimmune encephalomyelitis critically depends on CD137 ligand signaling. J. Neurosci. 3250, 18246-18252.
67. Matyszak M.K. and Perry V.H. (1996). The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system. Neuroscience 742, 599-608.
68. McColl S.R., Staykova M.A., Wozniak A., Fordham S., Bruce J. and Willenborg D.O. (1998). Treatment with anti-granulocyte antibodies inhibits the effector phase of experimental autoimmune encephalomyelitis. J. Immunol. 16111, 6421-6426.
69. McMenamin P.G. (1999). Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations. J. Comp Neurol. 4054, 553-562.
70. Michell-Robinson M.A., Touil H., Healy L.M., Owen D.R., Durafourt B.A., Bar-Or A., Antel J.P. and Moore C.S. (2015). Roles of microglia in brain development, tissue maintenance and repair. Brain 138Pt 5, 1138-1159.
71. Mikita J., Dubourdieu-Cassagno N., Deloire M.S., Vekris A., Biran M., Raffard G., Brochet B., Canron M.H., Franconi J.M., Boiziau C. and Petry K.G. (2011). Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult. Scler. 171, 2-15.
72. Mildner A., Mack M., Schmidt H., Bruck W., Djukic M., Zabel M.D., Hille A., Priller J. and Prinz M. (2009). CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 132, 2487-2500.
73. Miron V.E., Boyd A., Zhao J.W., Yuen T.J., Ruckh J.M., Shadrach J.L., van W.P., Wagers A.J., Williams A., Franklin R.J. and ffrench-Constant C. (2013). M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat. Neurosci. 169, 1211-1218.
74. Mizutani M., Pino P.A., Saederup N., Charo I.F., Ransohoff R.M. and Cardona A.E. (2012). The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. J. Immunol. 1881, 29-36.
75. Moline-Velazquez V., Cuervo H., Vila del Sol V., Ortega M.C., Clemente D. and de Castro F. (2011). Myeloid-derived suppressor cells limit the inflammation by promoting T lymphocyte apoptosis in the spinal cord of a murine model of multiple sclerosis. Brain Pathol. 216, 678-691.
76. Moline-Velazquez V., Ortega M.C., Vila del Sol V., Melero-Jerez C., de Castro F. and Clemente D. (2014). The synthetic retinoid Am80 delays recovery in a model of multiple sclerosis by modulating myeloid-derived suppressor cell fate and viability. Neurobiol. Dis. 67, 149-164.
77. Moreno B., Espejo C., Mestre L., Suardiaz M., Clemente D., de Castro F., Fernandez-Fernandez O., Montalban X., Villoslada P. and Guaza C. (2012). Guidelines on the appropriate use of animal models for developing therapies in multiple sclerosis. Rev. Neurol. 542, 114-124.
78. Mosser D.M. and Edwards J.P. (2008). Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 812, 958-969.
79. Naegele M., Tillack K., Reinhardt S., Schippling S., Martin R. and Sospedra M. (2012). Neutrophils in multiple sclerosis are characterized by a primed phenotype. J. Neuroimmunol. 2421-2, 60-71.
80. Naess A., Nyland H., Glette J., Larsen J.P., Rygh T. and Solberg C.O. (1986). Granulocyte function in patients with multiple sclerosis. Acta Pathol. Microbiol. Immunol. Scand. C. 942, 89-90.
81. Noseworthy J.H., Lucchinetti C., Rodríguez M. and Weinshenker B.G. (2000). Multiple sclerosis. N. Engl. J. Med. 34313, 938-952.
82. Peranzoni E., Zilio S., Marigo I., Dolcetti L., Zanovello P., Mandruzzato S. and Bronte V. (2010). Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 222, 238-244.
83. Plumb J., Armstrong M.A., Duddy M., Mirakhur M. and McQuaid S. (2003). CD83-positive dendritic cells are present in occasional perivascular cuffs in multiple sclerosis lesions. Mult. Scler. 92, 142-147.
84. Podikoglou D.G., Lianou P.E., Tsakanikas C.D. and Papavassiliou J.T. (1994). Polymorphonuclear leukocyte functions and multiple sclerosis. Neurology 441, 129-132.
85. Ponomarev E.D., Shriver L.P., Maresz K. and Dittel B.N. (2005). Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. J. Neurosci. Res. 813, 374-389.
86. Qin H., Yeh W.I., De S.P., Holdbrooks A.T., Liu Y., Muldowney M.T., Reynolds S.L., Yanagisawa L.L., Fox T.H., III, Park K., Harrington L.E., Raman C. and Benveniste E.N. (2012). Signal transducer and activator of transcription-3/suppressor of cytokine signaling-3 (STAT3/SOCS3) axis in myeloid cells regulates neuroinflammation. Proc. Natl. Acad. Sci. USA 10913, 5004-5009.
87. Quintana F.J., Yeste A. and Mascanfroni I.D. (2015). Role and therapeutic value of dendritic cells in central nervous system autoimmunity. Cell Death. Differ. 222, 215-224.
88. Ransohoff R.M. (2007). Microgliosis: the questions shape the answers. Nat. Neurosci. 1012, 1507-1509.
89. Rivers T.M., Sprunt D.H. and Berry G.P. (1933). Observations on attempts to produce acute siddeminated encephalomyelitis in monkeys. J. Exp. Med. 581, 39-53.
90. Robinson A.P., Harp C.T., Noronha A. and Miller S.D. (2014). The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb. Clin. Neurol. 122, 173-189.
91. Rodriguez P.C., Quiceno D.G., Zabaleta J., Ortiz B., Zea A.H., Piazuelo M.B., Delgado A., Correa P., Brayer J., Sotomayor E.M., Antonia S., Ochoa J.B. and Ochoa A.C. (2004). Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 6416, 5839-5849.
92. Rosas M., Thomas B., Stacey M., Gordon S. and Taylor P.R. (2010). The myeloid 7/4-antigen defines recently generated inflammatory macrophages and is synonymous with Ly-6B. J. Leukoc. Biol. 881, 169-180.
93. Sae derup N., Cardona A.E., Croft K., Mizutani M., Cotleur A.C., Tsou C.L., Ransohoff R.M. and Charo I.F. (2010). Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One 510, e13693.
94. Sagar D., Lamontagne A., Foss C.A., Khan Z.K., Pomper M.G. and Jain P. (2012). Dendritic cell CNS recruitment correlates with disease severity in EAE via CCL2 chemotaxis at the blood-brain barrier through paracellular transmigration and ERK activation. J. Neuroinflammation 9, 245.
95. Sellner J., Kraus J., Awad A., Milo R., Hemmer B. and Stuve O. (2011). The increasing incidence and prevalence of female multiple sclerosis--a critical analysis of potential environmental factors. Autoimmun. Rev. 108, 495-502.
96. Serafini B., Columba-Cabezas S., Di Rosa F. and Aloisi F. (2000). Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. Am. J. Pathol. 1576, 1991-2002.
97. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Capello E., Mancardi G.L. and Aloisi F. (2006). Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. J. Neuropathol. Exp. Neurol. 652, 124-141.
98. Shechter R. and Schwartz M. (2013). Harnessing monocyte-derived macrophages to control central nervous system pathologies: no longer 'if' but 'how'. J. Pathol. 2292, 332-346.
99. Sica A. and Mantovani A. (2012). Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest 1223, 787-795.
100. Sionov R.V., Fridlender Z.G. and Granot Z. (2015). The multifaceted roles neutrophils play in the tumor microenvironment. Cancer Microenviron. (in press).
101. Sosa R.A., Murphey C., Ji N., Cardona A.E. and Forsthuber T.G. (2013). The kinetics of myelin antigen uptake by myeloid cells in the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 19112, 5848-5857.
102. Soulika A.M., Lee E., McCauley E., Miers L., Bannerman P. and Pleasure D. (2009). Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis. J. Neurosci. 2947, 14965-14979.
103. Sriram S. and Steiner I. (2005). Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann. Neurol. 586, 939-945.
104. Steinman L. and Zamvil S.S. (2006). How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 601, 12-21.
105. Suter T., Malipiero U., Otten L., Ludewig B., Muelethaler-Mottet A., Mach B., Reith W. and Fontana A. (2000). Dendritic cells and differential usage of the MHC class II transactivator promoters in the central nervous system in experimental autoimmune encephalitis. Eur. J. Immunol. 303, 794-802.
106. Talmadge J.E. (2007). Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin. Cancer Res. 1318, 5243-5248.
107. Trapp B.D., Bo L., Mork S. and Chang A. (1999). Pathogenesis of tissue injury in MS lesions. J. Neuroimmunol. 981, 49-56.
108. Trebst C., Sorensen T.L., Kivisakk P., Cathcart M.K., Hesselgesser J., Horuk R., Sellebjerg F., Lassmann H. and Ransohoff R.M. (2001). CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am. J. Pathol. 1595, 1701-1710.
109. Tsunoda I., Kuang L.Q., Igenge I.Z. and Fujinami R.S. (2005). Converting relapsing remitting to secondary progressive experimental allergic encephalomyelitis (EAE) by ultraviolet B irradiation. J. Neuroimmunol. 160, 122-134.
110. Verreck F.A., de Boer T., Langenberg D.M., Hoeve M.A., Kramer M., Vaisberg E., Kastelein R., Kolk A., de Waal-Malefyt R. and Ottenhoff T.H. (2004). Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc. Natl. Acad. Sci. USA 10113, 4560-4565.
111. Verreck F.A., de Boer T., Langenberg D.M., van der Z.L. and Ottenhoff T.H. (2006). Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma-and CD40Lmediated costimulation. J. Leukoc. Biol. 792, 285-293.
112. Vogel D.Y., Vereyken E.J., Glim J.E., Heijnen P.D., Moeton M., van der Valk P., Amor S., Teunissen C.E., van Horssen J. and Dijkstra C.D. (2013). Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J. Neuroinflammation 10, 35.
113. von Vietinghoff S. and Ley K. (2008). Homeostatic regulation of blood neutrophil counts. J. Immunol. 1818, 5183-5188.
114. Weber M.S., Prod'homme T., Youssef S., Dunn S.E., Rundle C.D., Lee L., Patarroyo J.C., Stuve O., Sobel R.A., Steinman L. and Zamvil S.S. (2007). Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med. 138, 935-943.
115. Wlodarczyk A., Lobner M., Cedile O. and Owens T. (2014). Comparison of microglia and infiltrating CD11c(+) cells as antigen presenting cells for T cell proliferation and cytokine response. J. Neuroinflammation 11, 57.
116. Wojkowska D.W., Szpakowski P., Ksiazek-Winiarek D., Leszczynski M. and Glabinski A. (2014). Interactions between neutrophils, Th17 cells, and chemokines during the initiation of experimental model of multiple sclerosis. Mediators. Inflamm. 2014, 590409.
117. Wu F., Cao W., Yang Y. and Liu A. (2010). Extensive infiltration of neutrophils in the acute phase of experimental autoimmune encephalomyelitis in C57BL/6 mice. Histochem. Cell Biol. 1333, 313-322.
118. Yamasaki R., Lu H., Butovsky O., Ohno N., Rietsch A.M., Cialic R., Wu P.M., Doykan C.E., Lin J., Cotleur A.C., Kidd G., Zorlu M.M., Sun N., Hu W., Liu L., Lee J.C., Taylor S.E., Uehlein L., Dixon D., Gu J., Floruta C.M., Zhu M., Charo I.F., Weiner H.L. and Ransohoff R.M. (2014). Differential roles of microglia and monocytes in the inflamed central nervous system. J. Exp. Med. 2118, 1533-1549.
119. Young E.A., Fowler C.D., Kidd G.J., Chang A., Rudick R., Fisher E. and Trapp B.D. (2008). Imaging correlates of decreased axonal Na+/K+ ATPase in chronic multiple sclerosis lesions. Ann. Neurol. 634, 428-435.
120. Zeyda M., Geyeregger R., Poglitsch M., Weichhart T., Zlabinger G.J., Koyasu S., Horl W.H., Stulnig T.M., Watschinger B. and Saemann M.D. (2007). Impairment of T cell interactions with antigenpresenting cells by immunosuppressive drugs reveals involvement of calcineurin and NF-kappaB in immunological synapse formation. J. Leukoc. Biol. 811, 319-327.
121. Zhang J., Zhang Z.G., Li Y., Ding X., Shang X., Lu M., Elias S.B. and Chopp M. (2015). Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis. Neurobiol. Dis. 76, 57-66.
122. Zhang Z., Zhang Z.Y., Schittenhelm J., Wu Y., Meyermann R. and Schluesener H.J. (2011). Parenchymal accumulation of CD163+ macrophages/microglia in multiple sclerosis brains. J. Neuroimmunol. 2371-2, 73-79.
123. Zhu B., Bando Y., Xiao S., Yang K., Anderson A.C., Kuchroo V.K. and Khoury S.J. (2007). CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J. Immunol. 1798, 5228-5237.
124. Zhu B., Kennedy J.K., Wang Y., Sandoval-Garcia C., Cao L., Xiao S., Wu C., Elyaman W. and Khoury S.J. (2011). Plasticity of Ly-6C(hi) myeloid cells in T cell regulation. J. Immunol. 1875, 2418-2432.
125. Ziaber J., Pasnik J., Baj Z., Pokoca L., Chmielewski H. and Tchorzewski H. (1998). The immunoregulatory abilities of polymorphonuclear neutrophils in the course of multiple sclerosis. Mediators. Inflamm. 75, 335-338.
126. Zozulya A.L., Ortler S., Lee J., Weidenfeller C., Sandor M., Wiendl H. and Fabry Z. (2009). Intracerebral dendritic cells critically modulate encephalitogenic versus regulatory immune responses in the CNS. J. Neurosci. 291, 140-152.